使用ATG与PTCy预防相合无关供者异基因造血细胞移植中移植物抗宿主病的十年经验
该回顾性分析纳入582例接受无关供者移植的血液恶性肿瘤患者,采用低剂量ATG(2 mg/kg)联合PTCy预防GVHD,评估十年期间的安全性和有效性。中位中性粒细胞和血小板植入时间分别为18天和20天,III-IV级急性GVHD的D+100累积发生率为7%,24个月中重度慢性GVHD发生率为15.7%,24个月GRFS为49%,OS为68.3%。作者认为该联合方案安全有效,但需前瞻性研究进一步验证。
要点
- 低剂量ATG(2 mg/kg)联合PTCy用于无关供者移植GVHD预防,III-IV级急性GVHD的D+100累积发生率为7%。
- 24个月中重度慢性GVHD累积发生率为15.7%,24个月GRFS为49%,OS为68.3%。
- D+180临床显著CMV和EBV再激活率分别为20.4%和22.7%。
核心结论
- 十年经验支持低剂量ATG联合PTCy在无关供者移植中预防GVHD的安全性和有效性。
- 这些发现需在前瞻性研究中进一步验证。
研究设计与样本
- 回顾性分析582例接受无关供者移植的血液恶性肿瘤患者,采用低剂量ATG(2 mg/kg)联合PTCy进行GVHD预防,观察期为十年。
主要发现
- 中位中性粒细胞植入时间为18天(95% CI,17-19),中位血小板植入时间为20天(95% CI,19-21)。
- III-IV级急性GVHD的D+100累积发生率为7%(95% CI:5-9),24个月中重度慢性GVHD发生率为15.7%(95% CI:13-19)。
- D+180临床显著CMV再激活率为20.4%(95% CI:17-24),EBV再激活率为22.7%(95% CI:19-26)。
- 24个月NRM累积发生率为16.2%(95% CI:13-19),复发累积发生率为21.3%(95% CI:18-25)。
- 24个月GRFS为49%(95% CI:44-53),OS为68.3%(95% CI:64-72)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) are both effective drugs for graft-versus-host disease (GvHD) prophylaxis, but their combined use remains underexplored. We conducted a retrospective analysis of 582 patients with haematological malignancies who underwent unrelated donor transplantation with Status GvHD prophylaxis consisting of low-dose ATG (2 mg/kg) and PTCy over a 10-year period. The median time to neutrophil and platelet engraftment was 18 days (95% CI, 17-19) and 20 days (95% CI, 19-21) respectively. The cumulative incidence of grade III-IV acute Status GvHD at D+100 was 7% (95% CI: 5-9), and the 24-month incidence of moderate-to-severe chronic GvHD was 15.7% (95% CI: 13-19). Clinically significant cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation by D+180 occurred in 20.4% (95% CI: 17-24) and 22.7% (95% CI: 19-26) respectively. At 24 months, the cumulative incidence of NRM was 16.2% (95% CI: 13-19), and relapse was 21.3% (95% CI: 18-25). Graft-versus-host disease-free, relapse-free survival (GRFS) at 24 months was 49% (95% CI: 44-53), and overall survival (OS) was 68.3% (95% CI: 64-72). Our decade-long experience supports the safety and efficacy of combining low-dose ATG with PTCy for GvHD prophylaxis in unrelated donor transplantation. These findings warrant further validation in prospective studies.
引用
- Desai N, Rodriguez-Rodriguez S, Al-Shaibani E, et al. A decade of experience using ATG and PTCy for graft-versus-host disease prophylaxis in matched unrelated donor allogeneic haematopoietic cell transplantation. Br J Haematol. 2025. PMID: 40859738. doi:10.1111/bjh.70124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。